D'LAYNA BRENING: Open Payments
NPI 1043672561 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$177 in 9 payments from 8 companies in 2025. Trend: 2023 $105 · 2024 $0 · 2025 $177
Food & beverage: $177
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
Products named: REXULTI, TRINTELLIX, Rybelsus, CAPLYTA, NEXLETOL, XIFAXAN, VOQUEZNA.
Industry payments across NE — which companies pay providers there.
